CD33 and acute myeloid leukemia: Further studies including quantitative flow cytometric methods with a panel of distinct reagents against CD33 are needed to confirm our results, since CD33 expression levels have also been associated previously with a further response to the anti-CD33 Mylotarg antibody in acute myeloid leukemia (AML) [74,75].